Journal
NEUROBIOLOGY OF DISEASE
Volume 54, Issue -, Pages 216-224Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2012.12.014
Keywords
Interleukin 1 beta; Isoflurane; Neuroprotection; Nuclear factor-kappa B; Postconditioning
Categories
Funding
- International Anesthesia Research Society (Frontiers in Anesthesia Research Award), Cleveland, OH
- National Institutes of Health, Bethesda, MD [R01 GM065211, R01 GM098308]
- American Heart Association Mid-Atlantic Affiliate, Baltimore, MD [10GRNT3900019]
- Robert M. Epstein Professorship endowment, University of Virginia, Charlottesville, VA
Ask authors/readers for more resources
Application of isoflurane, a volatile anesthetic, after brain ischemia can reduce ischemic brain injury in rodents (isoflurane postconditioning). This study is designed to determine whether isoflurane postconditioning improves long-term neurological outcome after focal brain ischemia and whether this protection is mediated by attenuating neuroinflammation. Adult male Sprague-Dawley rats were subjected to a 90-min middle cerebral arterial occlusion (MCAO). Isoflurane postconditioning was performed by exposing rats to 2% isoflurane for 60 min immediately after the MCAO. Isoflurane postconditioning reduced brain infarct volumes, apoptotic cells in the ischemic penumbral brain tissues and neurological deficits of rats at 4 weeks after the MCAO. Isoflurane postconditioning reduced brain ischemia/reperfusion-induced nuclear transcription factor (NF)-kappa B (NF-kappa B) activation as well as interleukin 1 beta (IL-1 beta) and interleukin-6 production in the ischemic penumbral brain tissues at 24 h after the MCAO. IL-1 beta deficient mice had smaller brain infarct volumes and better neurological functions than wild-type mice at 24 h after a 90-min focal brain ischemia. Isoflurane posttreatment failed to induce neuroprotection in the IL-1 beta deficient mice. Our results suggest that isoflurane postconditioning improved long-term neurological outcome after transient focal brain ischemia. This protection may be mediated by inhibiting NF-kappa B activation and the production of the proinflammatory cytokine IL-1 beta. (C) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available